Category

Investing

Category

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (‘CNS’) disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025. Paul Carter is a highly accomplished global biopharmaceutical leader with nearly three decades of senior…